These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22321963)

  • 21. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
    Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
    Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy.
    Duprez DA; Weintraub HS; Cushman WC; Purkayastha D; Zappe D; Samuel R; Izzo JL
    Blood Press Monit; 2011 Aug; 16(4):186-96. PubMed ID: 21747241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
    Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
    Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing.
    Hermida RC; Ayala DE; Fontao MJ; Mojón A; Fernández JR
    Chronobiol Int; 2010 Jul; 27(6):1287-303. PubMed ID: 20653455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
    Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
    Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy.
    Weir MR; Levy D; Crikelair N; Rocha R; Meng X; Glazer R
    Am J Hypertens; 2007 Jul; 20(7):807-15. PubMed ID: 17586417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension.
    White WB; Davidai G; Schumacher H
    J Hum Hypertens; 2009 Dec; 23(12):817-25. PubMed ID: 19357698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
    J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Ali MA; Jin J; Keefe DL
    J Hypertens; 2008 Mar; 26(3):589-99. PubMed ID: 18300872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.
    Zhu JR; Sun NL; Yang K; Hu J; Xu G; Hong H; Wang R; Tu YM; Ritter S; Keefe D;
    Hypertens Res; 2012 Jan; 35(1):28-33. PubMed ID: 21900941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension.
    Verdecchia P; Calvo C; Möckel V; Keeling L; Satlin A
    Blood Press; 2007; 16(6):381-91. PubMed ID: 18058456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients.
    Gualtierotti R; Zoppi A; Mugellini A; Derosa G; D'Angelo A; Fogari R
    Expert Opin Pharmacother; 2013 Oct; 14(14):1875-84. PubMed ID: 23883161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
    J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study.
    Littlejohn TW; Jones SW; Zhang J; Hsu H; Keefe DL
    J Hum Hypertens; 2013 May; 27(5):321-7. PubMed ID: 23076450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension.
    Ferdinand KC; Weitzman R; Purkayastha D; Sridharan K; Jaimes EA
    J Am Soc Hypertens; 2012; 6(3):219-27. PubMed ID: 22305998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study.
    Saito I; Saruta T;
    Hypertens Res; 2006 Oct; 29(10):789-96. PubMed ID: 17283866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of high-dose valsartan monotherapy in hypertension treatment: the ValTop study.
    Parati G; Asmar R; Bilo G; Kandra A; Di Giovanni R; Mengden T
    Hypertens Res; 2010 Oct; 33(10):986-94. PubMed ID: 20686486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
    Rajagopalan S; Zannad F; Radauceanu A; Glazer R; Jia Y; Prescott MF; Kariisa M; Pitt B
    Am J Cardiol; 2007 Jul; 100(2):222-6. PubMed ID: 17631074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial.
    Serebruany VL; Pokov AN; Aradi D; Can M; DiNicolantonio J; Kipshidze N; Atar D
    Am J Ther; 2014; 21(6):482-90. PubMed ID: 23698186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.